Table of Contents
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED
5.1 SMALL INTESTINE
5.2 RECTUM
5.3 LUNGS
5.4 APPENDIX
5.5 COLON
5.6 STOMACH
5.7 PANCREAS
5.8 LIVER
5.9 OTHERS
6. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE
6.1 CHEMOTHERAPY
6.3 BIOLOGICAL THERAPY
6.4 HEPATIC ARTERY EMBOLIZATION AGENT
7. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS
7.1 HOSPITALS
7.2 CLINICS
7.3 CENCER INSTITUTIONS AND TREATMENT CENTERS
7.4 OTHERS
8. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION
8.1 NORTH AMERICA
8.1.1 INTRODUCTION
8.2 EUROPE
82.1 INTRODUCTION
8.3 ASIA-PACIFIC
8.3.1 INTRODUCTION
8.4 MIDDLE EAST & AFRICA
8.4.1 INTRODUCTION
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9..1.1 STRATEGIC PARTNERSHIP
10..1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 BTG INTERNATIONAL LTD.
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 IPSEN BIOPHARMACEUTICALS, INC.,
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 NOVARTIS INTERNATIONAL AG (SANDOZ)
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 STRATEGY
10.3.5 KEY DEVELOPMENT
10.4 PHARMASCIENCE INC.,
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 OTHERS
List of Tables
TABLE 1 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED, 2020-2027 (USD MILLION)
TABLE 2 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKETBY END USERS 2020-2027 (USD MILLION)
TABLE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION 2020-2027 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED
FIGURE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE
FIGURE 5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS
FIGURE 6 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION
FIGURE 7 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
